Overview

• Lilly named Marks senior vice president of molecule discovery and head of infectious disease, effective this month, and did not detail his specific duties.
• Marks previously directed the FDA’s Center for Biologics Evaluation and Research, where he helped shape Operation Warp Speed and oversaw vaccines, blood products, and gene and cell therapies.
• In his resignation letter, he said he left the FDA after disagreeing with the HHS secretary over vaccine safety transparency.
• Leerink Partners said his experience could add significant value to Lilly, which is best known for obesity and diabetes drugs but has been exploring new research areas.
• The hire drew fresh scrutiny over the regulator-to-industry pipeline, with critics labeling it a revolving door, and was first reported by BioCentury and confirmed by Lilly to outlets including Reuters.